What is CapsoVision?
CapsoVision, Inc. is a Silicon Valley-based medical device innovator dedicated to transforming the landscape of gastrointestinal diagnostics. The company is best known for its flagship CapsoCam Plus capsule endoscopy system, a sophisticated technology designed to provide physicians with high-resolution imaging while enhancing patient comfort. By prioritizing out-of-the-box engineering and clinical excellence, CapsoVision has successfully deployed its diagnostic tools in over 70 countries, effectively bridging the gap between complex medical needs and accessible, high-confidence diagnostic outcomes. The firm operates as a privately held entity, maintaining a focus on long-term value creation and technological superiority in the competitive medical device industry.
How much funding has CapsoVision raised?
CapsoVision has raised a total of $74.2M across 11 funding rounds:
Private Equity
$2.5M
Private Equity
$1.5M
Private Equity
$589K
Private Equity
$3.7M
Private Equity
$15.9M
Private Equity
$4.6M
Debt
$350K
IPO
$27.5M
Stock/Share Issuance
$14M
Private Equity (2011): $2.5M, investors not publicly disclosed
Private Equity (2011): $1.5M, investors not publicly disclosed
Private Equity (2012): $589K, investors not publicly disclosed
Private Equity (2012): $3.7M, investors not publicly disclosed
Private Equity (2014): $15.9M, investors not publicly disclosed
Private Equity (2016): $4.6M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
IPO (2025): $27.5M, investors not publicly disclosed
Stock/Share Issuance (2026): $14M, investors not publicly disclosed
Key Investors in CapsoVision
Undisclosed Investors
Undisclosed Investors
PPP
Public-Private Partnership
What's next for CapsoVision?
With the successful acquisition of this latest strategic investment, CapsoVision is well-positioned to accelerate its research and development initiatives, particularly in the refinement of its existing capsule endoscopy platforms. The company is expected to focus on expanding its global footprint, targeting emerging markets where the demand for non-invasive diagnostic tools is rapidly increasing. Furthermore, the capital will likely support the integration of advanced data analytics into its diagnostic workflows, potentially enhancing the diagnostic confidence provided to clinicians. As the company moves into this next phase of growth, the focus remains on maintaining its competitive edge through continuous innovation and strategic market penetration, ensuring that its clinical solutions remain the standard for patient-centric care.
See full CapsoVision company page
